Brief: Gilead - Emvistegrast 200 Mg Met The Primary Endpoint In Phase 2 Swift Dose-Ranging Study
Mon 12:27
BRIEF-Gilead - Emvistegrast 200 Mg Met The Primary Endpoint In Phase 2 Swift Dose-Ranging Study Oct 19 (Reuters) - Gilead Sciences, Inc. GILD.O:
GILEAD - EMVISTEGRAST 200 MG MET THE PRIMARY ENDPOINT IN PHASE 2 SWIFT DOSE-RANGING STUDY
GILEAD - EMVISTEGRAST 200 MG DEMONSTRATED SIGNIFICANT DIFFERENCES ACROSS MULTIPLE SECONDARY MEASURES OF DISEASE ACTIVITY BASED ON NOMINAL P-VALUES
GILEAD: EMVISTEGRAST 200MG ACHIEVES 66% CLINICAL RESPONSE VERSUS 37% PLACEBO AT WEEK 12 IN ULCERATIVE COLITIS
GILEAD - EMVISTEGRAST 200 MG SHOWED GENERALLY WELL-TOLERATED SAFETY PROFILE
GILEAD: PLANS TO INITIATE PHASE 3 EMVISTEGRAST MONOTHERAPY STUDY IN 2027
Source text: [ID:]
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gilead Sciences
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
Abivax shares fall after rival drug data, trader says
Brief: Gilead - Emvistegrast 200 Mg Met The Primary Endpoint In Phase 2 Swift Dose-Ranging Study
Gilead's pill succeeds in mid-stage bowel disease trial
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal